SEC Company Response from Cardiff Oncology, Inc. (CRDF) (CIK 0001213037) (CRDF) — Dec 13, 2017
Cardiff Oncology, Inc. (CRDF) (CIK 0001213037)
Date: Dec. 13, 2017 · CIK: 0001213037 · Accession: 0001193125-17-368412
AI Filing Summary & Sentiment
File numbers found in text: 333-221115
Letter
Re: TROVAGENE, INC.
December 13, 2017
VIA FACSIMILE AND EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Washington, D.C. 20549
Registration Statement on Form S-1 (Registration No. 333-221115) -
Concurrence in Acceleration Request
Ladies and Gentlemen:
H.C. Wainwright & Co., LLC (“Wainwright”), as placement agent for the referenced offering, hereby concurs in the request by Trovagene, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:15 P.M. Eastern Time on Thursday, December 14, 2017, or as soon as practicable thereafter, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.
Very truly yours,
H.C. WAINWRIGHT & CO., LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP December 13, 2017 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Re: TROVAGENE, INC. Registration Statement on Form S-1 (Registration No. 333-221115) - Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (“Wainwright”), as placement agent for the referenced offering, hereby concurs in the request by Trovagene, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:15 P.M. Eastern Time on Thursday, December 14, 2017, or as soon as practicable thereafter, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering. Very truly yours, H.C. WAINWRIGHT & CO., LLC By: /s/ Mark Viklund Name: Mark Viklund Title: Chief Executive Officer